8.1.1 The manufacturing complexity associated with viral vectors and gene and gene-modified cell therapies has limited the number of companies with installed capacity and capabilities. Most emerging biotech/biopharma companies developing these products lack the resources and expertise to achieve efficient, scalable manufacturing and thus rely on CDMOs.[198]
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.